Letrozole in Post-Menopausal Patients with Operable Hormone-Sensitive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
Breast Cancer Female
Interventions
DRUG

Letrozole

Patients will receive a prescription for letrozole to be taken orally for 7-30 days to allow for variations in surgical scheduling. Patients are to undergo surgical resection of their tumor the day after the last dose of letrozole. Post-treatment tumor biopsies (a goal of 4-6 cores) will be obtained following 7-56 days of letrozole treatment on the day of surgery.

Trial Locations (1)

75390

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas

All Listed Sponsors
collaborator

Cancer Prevention Research Institute of Texas

OTHER

lead

University of Texas Southwestern Medical Center

OTHER

NCT03747042 - Letrozole in Post-Menopausal Patients with Operable Hormone-Sensitive Breast Cancer | Biotech Hunter | Biotech Hunter